These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 24654970)

  • 1. Changes in primary breast cancer heterogeneity may augment midtreatment MR imaging assessment of response to neoadjuvant chemotherapy.
    Parikh J; Selmi M; Charles-Edwards G; Glendenning J; Ganeshan B; Verma H; Mansi J; Harries M; Tutt A; Goh V
    Radiology; 2014 Jul; 272(1):100-12. PubMed ID: 24654970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Features from Computerized Texture Analysis of Breast Cancers at Pretreatment MR Imaging Are Associated with Response to Neoadjuvant Chemotherapy.
    Chamming's F; Ueno Y; Ferré R; Kao E; Jannot AS; Chong J; Omeroglu A; Mesurolle B; Reinhold C; Gallix B
    Radiology; 2018 Feb; 286(2):412-420. PubMed ID: 28980886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy--results from ACRIN 6657/I-SPY TRIAL.
    Hylton NM; Blume JD; Bernreuter WK; Pisano ED; Rosen MA; Morris EA; Weatherall PT; Lehman CD; Newstead GM; Polin S; Marques HS; Esserman LJ; Schnall MD;
    Radiology; 2012 Jun; 263(3):663-72. PubMed ID: 22623692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Breast cancer: early prediction of response to neoadjuvant chemotherapy using parametric response maps for MR imaging.
    Cho N; Im SA; Park IA; Lee KH; Li M; Han W; Noh DY; Moon WK
    Radiology; 2014 Aug; 272(2):385-96. PubMed ID: 24738612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast cancer: evaluation of response to neoadjuvant chemotherapy with 3.0-T MR imaging.
    Chen JH; Bahri S; Mehta RS; Kuzucan A; Yu HJ; Carpenter PM; Feig SA; Lin M; Hsiang DJ; Lane KT; Butler JA; Nalcioglu O; Su MY
    Radiology; 2011 Dec; 261(3):735-43. PubMed ID: 21878615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting pathologic response to neoadjuvant chemotherapy in breast cancer by using MR imaging and quantitative 1H MR spectroscopy.
    Baek HM; Chen JH; Nie K; Yu HJ; Bahri S; Mehta RS; Nalcioglu O; Su MY
    Radiology; 2009 Jun; 251(3):653-62. PubMed ID: 19276320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary human breast adenocarcinoma: imaging and histologic correlates of intrinsic susceptibility-weighted MR imaging before and during chemotherapy.
    Li SP; Taylor NJ; Makris A; Ah-See ML; Beresford MJ; Stirling JJ; d'Arcy JA; Collins DJ; Padhani AR
    Radiology; 2010 Dec; 257(3):643-52. PubMed ID: 20858850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast Cancer: Influence of Taxanes on Response Assessment with Dynamic Contrast-enhanced MR Imaging.
    Schrading S; Kuhl CK
    Radiology; 2015 Dec; 277(3):687-96. PubMed ID: 26176656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigating the prediction value of multiparametric magnetic resonance imaging at 3 T in response to neoadjuvant chemotherapy in breast cancer.
    Minarikova L; Bogner W; Pinker K; Valkovič L; Zaric O; Bago-Horvath Z; Bartsch R; Helbich TH; Trattnig S; Gruber S
    Eur Radiol; 2017 May; 27(5):1901-1911. PubMed ID: 27651141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breast tumour volume and blood flow measured by MRI after one cycle of epirubicin and cyclophosphamide-based neoadjuvant chemotherapy as predictors of pathological response.
    Stevens W; Farrow IM; Georgiou L; Hanby AM; Perren TJ; Windel LM; Wilson DJ; Sharma N; Dodwell D; Hughes TA; Dall BJ; Buckley DL
    Br J Radiol; 2021 Jul; 94(1123):20201396. PubMed ID: 34106751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant chemotherapy with sequential anthracycline-docetaxel with gemcitabine for large operable or locally advanced breast cancer: ANZ 0502 (NeoGem).
    McCarthy N; Boyle F; Zdenkowski N; Bull J; Leong E; Simpson A; Kannourakis G; Francis PA; Chirgwin J; Abdi E; Gebski V; Veillard AS; Zannino D; Wilcken N; Reaby L; Lindsay DF; Badger HD; Forbes JF;
    Breast; 2014 Apr; 23(2):142-51. PubMed ID: 24393617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diffusion-weighted MR imaging: pretreatment prediction of response to neoadjuvant chemotherapy in patients with breast cancer.
    Park SH; Moon WK; Cho N; Song IC; Chang JM; Park IA; Han W; Noh DY
    Radiology; 2010 Oct; 257(1):56-63. PubMed ID: 20851939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Texture Analysis with 3.0-T MRI for Association of Response to Neoadjuvant Chemotherapy in Breast Cancer.
    Eun NL; Kang D; Son EJ; Park JS; Youk JH; Kim JA; Gweon HM
    Radiology; 2020 Jan; 294(1):31-41. PubMed ID: 31769740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of Invasive Breast Cancer Heterogeneity Using Whole-Tumor Magnetic Resonance Imaging Texture Analysis: Correlations With Detailed Pathological Findings.
    Ko ES; Kim JH; Lim Y; Han BK; Cho EY; Nam SJ
    Medicine (Baltimore); 2016 Jan; 95(3):e2453. PubMed ID: 26817878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
    Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
    Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breast cancer: influence of tumour volume estimation method at MRI on prediction of pathological response to neoadjuvant chemotherapy.
    Henderson SA; Muhammad Gowdh N; Purdie CA; Jordan LB; Evans A; Brunton T; Thompson AM; Vinnicombe S
    Br J Radiol; 2018 Jul; 91(1087):20180123. PubMed ID: 29641224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation with 3.0-T MR imaging: predicting the pathological response of triple-negative breast cancer treated with anthracycline and taxane neoadjuvant chemotherapy.
    Kim MJ; Kim EK; Park S; Moon HJ; Kim SI; Park BW
    Acta Radiol; 2015 Sep; 56(9):1069-77. PubMed ID: 25228161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decrease in breast density in the contralateral normal breast of patients receiving neoadjuvant chemotherapy: MR imaging evaluation.
    Chen JH; Nie K; Bahri S; Hsu CC; Hsu FT; Shih HN; Lin M; Nalcioglu O; Su MY
    Radiology; 2010 Apr; 255(1):44-52. PubMed ID: 20308443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant chemotherapy in breast cancer: prediction of pathologic response with PET/CT and dynamic contrast-enhanced MR imaging--prospective assessment.
    Tateishi U; Miyake M; Nagaoka T; Terauchi T; Kubota K; Kinoshita T; Daisaki H; Macapinlac HA
    Radiology; 2012 Apr; 263(1):53-63. PubMed ID: 22438441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the Tumor Response After Neoadjuvant Chemotherapy in Breast Cancer Patients: Correlation Between Dynamic Contrast-enhanced Magnetic Resonance Imaging and Pathologic Tumor Cellularity.
    Choi WJ; Kim WK; Shin HJ; Cha JH; Chae EY; Kim HH
    Clin Breast Cancer; 2018 Feb; 18(1):e115-e121. PubMed ID: 28890184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.